These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

682 related items for PubMed ID: 31451492

  • 1. Prospective Comparison of PET Imaging with PSMA-Targeted 18F-DCFPyL Versus Na18F for Bone Lesion Detection in Patients with Metastatic Prostate Cancer.
    Rowe SP, Li X, Trock BJ, Werner RA, Frey S, DiGianvittorio M, Bleiler JK, Reyes DK, Abdallah R, Pienta KJ, Gorin MA, Pomper MG.
    J Nucl Med; 2020 Feb; 61(2):183-188. PubMed ID: 31451492
    [Abstract] [Full Text] [Related]

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.
    Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.
    Hell J Nucl Med; 2019 Feb; 22(1):6-9. PubMed ID: 30843003
    [Abstract] [Full Text] [Related]

  • 3. Interobserver Agreement for the Standardized Reporting System PSMA-RADS 1.0 on 18F-DCFPyL PET/CT Imaging.
    Werner RA, Bundschuh RA, Bundschuh L, Javadi MS, Leal JP, Higuchi T, Pienta KJ, Buck AK, Pomper MG, Gorin MA, Lapa C, Rowe SP.
    J Nucl Med; 2018 Dec; 59(12):1857-1864. PubMed ID: 30190304
    [Abstract] [Full Text] [Related]

  • 4. PSMA-Based [(18)F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer.
    Rowe SP, Macura KJ, Mena E, Blackford AL, Nadal R, Antonarakis ES, Eisenberger M, Carducci M, Fan H, Dannals RF, Chen Y, Mease RC, Szabo Z, Pomper MG, Cho SY.
    Mol Imaging Biol; 2016 Jun; 18(3):411-9. PubMed ID: 27080322
    [Abstract] [Full Text] [Related]

  • 5. Intraindividual Comparison of 18F-PSMA-1007 and 18F-DCFPyL PET/CT in the Prospective Evaluation of Patients with Newly Diagnosed Prostate Carcinoma: A Pilot Study.
    Giesel FL, Will L, Lawal I, Lengana T, Kratochwil C, Vorster M, Neels O, Reyneke F, Haberkon U, Kopka K, Sathekge M.
    J Nucl Med; 2018 Jul; 59(7):1076-1080. PubMed ID: 29269569
    [Abstract] [Full Text] [Related]

  • 6. Patterns of uptake of prostate-specific membrane antigen (PSMA)-targeted 18F-DCFPyL in peripheral ganglia.
    Werner RA, Sheikhbahaei S, Jones KM, Javadi MS, Solnes LB, Ross AE, Allaf ME, Pienta KJ, Lapa C, Buck AK, Higuchi T, Pomper MG, Gorin MA, Rowe SP.
    Ann Nucl Med; 2017 Nov; 31(9):696-702. PubMed ID: 28831739
    [Abstract] [Full Text] [Related]

  • 7. Comparison between 18 F-DCFPyL PET and MRI for the detection of transition zone prostate cancer.
    Liu Y, Dong Y, Liu J, Zhang X, Lin M, Xu B.
    Prostate; 2021 Dec; 81(16):1329-1336. PubMed ID: 34516670
    [Abstract] [Full Text] [Related]

  • 8. The Effects of Monosodium Glutamate on PSMA Radiotracer Uptake in Men with Recurrent Prostate Cancer: A Prospective, Randomized, Double-Blind, Placebo-Controlled Intraindividual Imaging Study.
    Harsini S, Saprunoff H, Alden T, Mohammadi B, Wilson D, Bénard F.
    J Nucl Med; 2021 Jan; 62(1):81-87. PubMed ID: 32385167
    [Abstract] [Full Text] [Related]

  • 9. A Prospective Comparison of 18F-Sodium Fluoride PET/CT and PSMA-Targeted 18F-DCFBC PET/CT in Metastatic Prostate Cancer.
    Harmon SA, Bergvall E, Mena E, Shih JH, Adler S, McKinney Y, Mehralivand S, Citrin DE, Couvillon A, Madan RA, Gulley JL, Mease RC, Jacobs PM, Pomper MG, Turkbey B, Choyke PL, Lindenberg ML.
    J Nucl Med; 2018 Nov; 59(11):1665-1671. PubMed ID: 29602821
    [Abstract] [Full Text] [Related]

  • 10. Follow-up of Lesions with Equivocal Radiotracer Uptake on PSMA-Targeted PET in Patients with Prostate Cancer: Predictive Values of the PSMA-RADS-3A and PSMA-RADS-3B Categories.
    Yin Y, Werner RA, Higuchi T, Lapa C, Pienta KJ, Pomper MG, Gorin MA, Rowe SP.
    J Nucl Med; 2019 Apr; 60(4):511-516. PubMed ID: 30190303
    [Abstract] [Full Text] [Related]

  • 11. Detection of prostate cancer with 18F-DCFPyL PET/CT compared to final histopathology of radical prostatectomy specimens: is PSMA-targeted biopsy feasible? The DeTeCT trial.
    Bodar YJL, Jansen BHE, van der Voorn JP, Zwezerijnen GJC, Meijer D, Nieuwenhuijzen JA, Boellaard R, Hendrikse NH, Hoekstra OS, van Moorselaar RJA, Oprea-Lager DE, Vis AN.
    World J Urol; 2021 Jul; 39(7):2439-2446. PubMed ID: 33079250
    [Abstract] [Full Text] [Related]

  • 12. 18F-DCFPyL PET/CT in Patients with Subclinical Recurrence of Prostate Cancer: Effect of Lesion Size, Smoothing Filter, and Partial-Volume Correction on PROMISE Criteria.
    Ortega C, Schaefferkoetter J, Veit-Haibach P, Anconina R, Berlin A, Perlis N, Metser U.
    J Nucl Med; 2020 Nov; 61(11):1615-1620. PubMed ID: 32198311
    [Abstract] [Full Text] [Related]

  • 13. Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted ¹⁸F-DCFPyL PET/CT.
    Rowe SP, Gorin MA, Hammers HJ, Som Javadi M, Hawasli H, Szabo Z, Cho SY, Pomper MG, Allaf ME.
    Ann Nucl Med; 2015 Dec; 29(10):877-82. PubMed ID: 26286635
    [Abstract] [Full Text] [Related]

  • 14. 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer.
    Chen Y, Pullambhatla M, Foss CA, Byun Y, Nimmagadda S, Senthamizhchelvan S, Sgouros G, Mease RC, Pomper MG.
    Clin Cancer Res; 2011 Dec 15; 17(24):7645-53. PubMed ID: 22042970
    [Abstract] [Full Text] [Related]

  • 15. PSMA-Based Detection of Prostate Cancer Bone Lesions With ¹⁸F-DCFPyL PET/CT: A Sensitive Alternative to (⁹⁹m)Tc-MDP Bone Scan and Na¹⁸F PET/CT?
    Rowe SP, Mana-Ay M, Javadi MS, Szabo Z, Leal JP, Pomper MG, Pienta KJ, Ross AE, Gorin MA.
    Clin Genitourin Cancer; 2016 Feb 15; 14(1):e115-8. PubMed ID: 26603549
    [No Abstract] [Full Text] [Related]

  • 16. Repeatability of Quantitative 18F-DCFPyL PET/CT Measurements in Metastatic Prostate Cancer.
    Jansen BHE, Cysouw MCF, Vis AN, van Moorselaar RJA, Voortman J, Bodar YJL, Schober PR, Hendrikse NH, Hoekstra OS, Boellaard R, Oprea-Lager DE.
    J Nucl Med; 2020 Sep 15; 61(9):1320-1325. PubMed ID: 31924729
    [Abstract] [Full Text] [Related]

  • 17. Role of 18F-DCFPyL PET/CT in patients with suspected prostate cancer.
    Zhang T, Yang S, Lin L, Wang S, Xia D, Chen D, Wang G, Zhao K, Su X.
    Hell J Nucl Med; 2022 Sep 15; 25(1):11-18. PubMed ID: 35388799
    [Abstract] [Full Text] [Related]

  • 18. Fluorine-18-labelled Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography or Magnetic Resonance Imaging to Diagnose and Localise Prostate Cancer. A Prospective Single-arm Paired Comparison (PEDAL).
    Wong LM, Sutherland T, Perry E, Tran V, Spelman T, Corcoran N, Lawrentschuk N, Woo H, Lenaghan D, Buchan N, Bax K, Symons J, Saeed Goolam A, Chalasani V, Hegarty J, Thomas L, Christov A, Ng M, Khanani H, Lee SF, Taubman K, Tarlinton L.
    Eur Urol Oncol; 2024 Oct 15; 7(5):1015-1023. PubMed ID: 38281891
    [Abstract] [Full Text] [Related]

  • 19. Prospective Evaluation of 18F-DCFPyL PET/CT in Biochemically Recurrent Prostate Cancer in an Academic Center: A Focus on Disease Localization and Changes in Management.
    Song H, Harrison C, Duan H, Guja K, Hatami N, Franc BL, Moradi F, Aparici CM, Davidzon GA, Iagaru A.
    J Nucl Med; 2020 Apr 15; 61(4):546-551. PubMed ID: 31628216
    [Abstract] [Full Text] [Related]

  • 20. 18F-DCFPyL PET/CT Imaging in Patients with Biochemically Recurrent Prostate Cancer After Primary Local Therapy.
    Mena E, Lindenberg ML, Turkbey IB, Shih JH, Harmon SA, Lim I, Lin F, Adler S, Eclarinal P, McKinney YL, Citrin D, Dahut W, Wood BJ, Krishnasamy V, Chang R, Levy E, Merino M, Pinto P, Eary JF, Choyke PL.
    J Nucl Med; 2020 Jun 15; 61(6):881-889. PubMed ID: 31676732
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.